Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma

Journal of Cellular Biochemistry

Volumn 97, Issue 1, 2006, Pages 98-108

  Magistrelli, Paolo ^a   Coppola, Roberta ^b   Tonini, Giuseppe ^c   Vincenzi, Bruno ^c,e   Santini, Daniele ^c   Borzomati, Domenico ^b   Vecchio, Fabio ^a   Valeri, Sergio ^b   Castri, Federica ^a   Antinori, Armando ^a   Nuzzo, Gennaro ^a   Caraglia, Michele ^d,f   Picciocchi, Aurelio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Campus Bio Medico University ^*  (Italy)

^c Medical Oncology   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant therapy; Apoptosis; Bax; Bcl 2; Nodal status; p53; Pancreas cancer; Prognosis; Survival

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 30044445726     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20621     Document Type: Article

References (39)

1. Breckenridge DG, Germain M, Mathai JP, Nguyen M, Shore GC. 2003. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22(53):8608-8618.
2. Budhram-Mahadeo V, Morris PJ, Smith MD, Midgley CA, Boxer LM, Latchman DS. 1999. p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. J Biol Chem 274:15237-15244.
3. Butt AJ, Firth SM, King MA, Baxter RC. 2000. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 275:39174-39181.
4. Campani D, Esposito I, Boggi U, Cecchetti D, Menicagli M, De Negri F, Colizzi L, Del Chiaro M, Mosca F, Fornaciari G, Bevilacqua G. 2001. Bcl-2 expression in pancreas development and pancreatic cancer progression. J Pathol 194(4):444-450.
5. Canman CE, Gilmer TM, Coutts SB, Kastan MB. 1995. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9:606-611.
6. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. 1993. Thymocyte apoptosis induced by p53 dependent and independent pathway. Nature 362:849-852.
7. Coppola D, Lu L, Fruehauf JP, Kyshtoobayeva A, Karl RC, Nicosia SV, Yeatman TJ. 1998. Analysis of p53, P21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival. Am J Clin Pathol 110:16-23.
8. Cox DR. 1972. Regression models and life tables. J R Stat Soc 34:187-220.
9. Evans JD, Cornford PA, Dodson A, Greenhalf W, Foster CS, Neoptolemos JP. 2001. Detailed tissue expression of bcl-2, bax, bak, and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary, and pancreatic ductaladenocarcinomas. Pancreatology 1(3):254-262.
10. Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Buchler MW. 1998. bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 43:414-421.
11. Fujii H, Inagaki M, Kasai S, Miyokawa N, Tokusashi Y, Gabrielson E, Hruban RH. 1997. Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 151:1447-1454.
12. Geer RJ, Brennan MF. 1993. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165:68-73.
13. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Motoo Y, Okai T, Sawabu N. 1999. Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br J Cancer 80:1075-1079.
14. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
15. Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N, Neoptolemos JP. 2000. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2, and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 89:469-474.
16. Kimura W, Morikane K, Esaki Y, Chan WC, Pour PM. 1998. Histologic and biologic patterns of microscopic pancreatic ductal adenocarcinomas detected incidentally at autopsy. Cancer 82:1839-1849.
17. Kuhl JS, Krajewski S, Duran GE, Reed JC, Sikic BI. 1997. Spontaneous overexpression of the long form of Bcl-X protein in a highly resistant P388 leukaemia. Br J Cancer 75:268-274.
18. Makinen K, Hakala T, Lipponen P, Alhava E, Eskelinen M. 1998. Clinical contribution of bcl-2, p53, and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res 18:615-618.
19. Miyashita T, Reed JC. 1995. Tumor suppressor p53 is a direct transcriptional activator of human box gene. Cell 80:293-299.
20. Miyashita T, Harigai M, Hanada M, Reed JC. 1994. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54:3130-3135.
21. Nio Y, Iguchi C, Yamasawa K, Sasaki S, Takamura M, Toga T, Dong M, Itakura M, Tamura K. 2001. Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas 22(3):230-239.
22. Nitecki SS, Sarr MG, Colby TV, et al. 1995. Long-term survival after resection for ductal adenocarcinoma of the pancreas: Is in really improving? Ann Surg 221: 59-66.
23. Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, Recant WM. 1997. Overexpression of Bcl-X protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J Sci Am 3:230-237.
24. Oltvai ZN, Milliman CL, Korsmeyer SJ. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerated programmed cell death. Cell 74:609-611.
25. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. 1996. Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell system. Cancer Res 56:556-562.
26. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. 1997. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 35:1-39.
27. Ryan JJ, Danish R, Gottlieb CA, Clarke MF. 1993. Cell cycle analysis of p53-induced cell death in murine etythroleukemia cells. Mol Cell Biol 13:711-719.
28. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. 2002. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86(6):886-892.
29. Sessa F, Bonato M, Bisoni D, Ranzani GN, Capella C. 1998. Ki-ras and p53 gene mutations in pancreatic ductal carcinoma: A relationship with tumour phenotype and survival. Eur J Histochem 42:67-76.
30. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677.
31. Sinicrope FA, Evans DB, Leach SD, Cleary KR, Fenoglio CJ, Lee JJ, Abbruzzese JL. 1996. Bcl-2 and p53 expression in resectable pancreatic carcinoma: Association with clinical outcome. Clin Cancer Res 2:2015-2022.
32. Sobin LH, Wittekind C. 2002. TNM Classification of Malignant Tumours: UICC International Union Against Cancer. Edition 5. New York, NY: Wiley-Liss.
33. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. 2000. Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-579.
34. Stat Bite: 2002. Pancreatic cancer incidence in U.S. blacks and whites. 1973-1999. J Natl Cancer Inst 94(22):1671.
35. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dorken B, Daniel PT. 1999. Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17(5):1364-1374.
36. Tsuji K, Mizumoto K, Sudo H, Kouyama K, Ogata E, Matsuoka M. 2002. p53-independent apoptosis is induced by the p19ARF tumor suppressor. Biochem Biophys Res Commun 295(3):621-629.
37. Ueda N, Shah SV. 1994. Apoptosis. J Lab Clin Med 124:169-177.
38. Yokoyama M, Yamanaka Y, Friess H, Buchler M, Korc M. 1994. p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res 14:2477-2484.
39. Zhan Q, Alamo I, Yu K, Boise LH, Cherney B, Tosato G, O'Connor PM, Fornace AJ, Jr. 1996. The apoptosis associated gammaray response of Bcl-X(L) depends on normal p53 function. Oncogene 13:2287-2293.